Aeterna Zentaris Reports Fourth Quarter and Full-Year 2017 Financial and Operating Results

Biotech Investing

Aeterna Zentaris (NASDAQ:AEZS) reported financial and operating results for the fourth quarter and year ended December 31, 2017. As quoted in the press release: Commenting on recent key developments, Michael V. Ward, President and Chief Executive Officer for Aeterna Zentaris, stated, “We made a positive transformation in the fourth quarter 2017 when we pursued out-licensing to maximize …

Aeterna Zentaris (NASDAQ:AEZS) reported financial and operating results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

Commenting on recent key developments, Michael V. Ward, President and Chief Executive Officer for Aeterna Zentaris, stated, “We made a positive transformation in the fourth quarter 2017 when we pursued out-licensing to maximize shareholder value and now are focused on the flawless execution of the contractual obligations with Strongbridge. We have been working with the exceptional leadership team at Strongbridge to transition Macrilen™ and are on target to support their efforts to successfully launch Macrilen™ as early as possible.”

Click here to read the full press release.

leadership team Biotech Investing